• Markets
    • icon
  • Companies
RCE · ASX

Recce Pharmaceuticals Ltd. (ASX:RCE)

AU$0.46

 0.0 (0.0%)
ASX:Live
26/07/2024 03:56:52 PM
HALO Ords HALO Consensus Value HALO Capital Efficiency GROWTH AUS All-Consensus +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

RCE Overview

RCE Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Strong

About RCE

Website

Recce Pharmaceuticals Ltd.

Telephone

61.2.9256.2505

Address

Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000

Description

Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.

RCE Price Chart

Key Stats

Market Cap

AU$102.01M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.41 - 0.75

Trade Value (12mth)

AU$23,181.00

1 week

-2.13%

1 month

-14.02%

YTD

-12.38%

1 year

-34.1%

All time high

1.86

Key Fundamentals

EPS 3 yr Growth

119.500%

EBITDA Margin

N/A

Operating Cashflow

-$13m

Free Cash Flow Return

-335.00%

ROIC

-345.30%

Interest Coverage

-93.40

Quick Ratio

0.40

Other Data

Shares on Issue (Fully Dilluted)

179m

HALO Sector

Healthcare

Next Company Report Date

30-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.01

RCE Announcements

Latest Announcements

Date Announcements

15 July 24

US Department of Defense Grants US $2m for R327G

×

US Department of Defense Grants US $2m for R327G

11 July 24

Change of Auditor

×

Change of Auditor

10 July 24

Share Purchase Plan - Letter and Offer Booklet

×

Share Purchase Plan - Letter and Offer Booklet

09 July 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

09 July 24

Cleansing Notice

×

Cleansing Notice

08 July 24

R327 Efficacy against WHO Priority Pathogen Acinetobacter B

×

R327 Efficacy against WHO Priority Pathogen Acinetobacter B

02 July 24

Placement & SPP to raise $10 million - Funded to FY26

×

Placement & SPP to raise $10 million - Funded to FY26

02 July 24

Proposed issue of securities - RCE

×

Proposed issue of securities - RCE

02 July 24

Equity Raising Presentation

×

Equity Raising Presentation

01 July 24

Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial

×

Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial

01 July 24

Trading Halt

×

Trading Halt

28 June 24

Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete

×

Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete

24 June 24

Ethics Approval Broadens to All Topical Infections

×

Ethics Approval Broadens to All Topical Infections

18 June 24

R327 added to WHO List of Antibacterial Products

×

R327 added to WHO List of Antibacterial Products

18 June 24

Further R&D Rebate Approved

×

Further R&D Rebate Approved

11 June 24

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

×

Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial

03 June 24

Military Health Research Symposium Abstract & Presentation

×

Military Health Research Symposium Abstract & Presentation

15 May 24

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

×

Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort

10 May 24

Application for quotation of securities - RCE

×

Application for quotation of securities - RCE

10 May 24

Cleansing Statement

×

Cleansing Statement

09 May 24

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

×

MCRI Pilot Study- Positive Efficacy Data for Lung Infections

07 May 24

China Patent Granted for RECCE Anti-Infectives

×

China Patent Granted for RECCE Anti-Infectives

26 April 24

Safety Committee Approves High Dose of 4,000mg

×

Safety Committee Approves High Dose of 4,000mg

22 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 April 24

Recce Completes 5,000 R327 Doses Per Week under GMP

×

Recce Completes 5,000 R327 Doses Per Week under GMP

RCE Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.09 -0.06 -0.07 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.09 -0.06 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -156.6 27.5 -17.9 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.06 -0.07 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.05 -0.05 -0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -54.3 -28.9 -17.3 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.5 -5.8 -11.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.06 -0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.12 0.06 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 594.2 -52.0 -125.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 155 174 176 Lock Lock Lock
Basic m Lock Lock Lock Lock 155 174 176 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 15 14 17 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.2 36.5 -15.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -189.4 7.3 -22.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -184.1 7.9 -22.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -15 -14 -17 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -2 -3 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -14 -11 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -213.0 18.7 -19.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -8 -9 -13 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 26 0 3 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -8 -9 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -108.0 -14.1 -40.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 21 12 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 22 13 3 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -21 -12 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 1 3 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 21 10 -3 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 21 10 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 787.2 -51.0 -124.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -62.3 -87.0 -511.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -133.5 -92.0 -444.4 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -118.4 -71.9 -345.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -68.8 -58.9 -335.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -1,241.2 -1,170.8 -93.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.4 0.8 0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -101.2 -114.4 50.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 19.6 5.0 0.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 19.6 5.0 0.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.5 95.1 80.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -728.6 -368.2 -261.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -62.3 -87.0 -511.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.3 -1.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -65.9 -109.2 505.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 399.3 941.9 1,202.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -399.3 -941.9 -1,202.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.01%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

RCE Shortsell

Frequently Asked Questions

The current share price of Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.46.
The 52-week high share price for Recce Pharmaceuticals Ltd. (RCE:ASX) is AU$0.75.
The 52-week low share price for Recce Pharmaceuticals Ltd. (RCE:ASX)? is AU$0.41.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not pay a dividend.
Recce Pharmaceuticals Ltd. (RCE:ASX) does not offer franking credits.
Recce Pharmaceuticals Ltd. (RCE:ASX) is classified in the Healthcare.
The current P/E ratio for Recce Pharmaceuticals Ltd. (RCE:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.